Cost-Effectiveness of Baloxavir Marboxil Versus Oseltamivir or no Treatment for the Management of Influenza in the United States
Baloxavir was cost-effective compared with oseltamivir or no antiviral treatment. The potential of baloxavir to reduce viral transmission offers a substantial economic benefit from a US payer perspective.
Authors
- Jeff Frimpter (ORCID: https://orcid.org/0000-0002-1615-8430)
- Hassan Zaraket (ORCID: https://orcid.org/0000-0003-3807-6409)
- Svenn Alexander Kommandantvold (ORCID: https://orcid.org/0000-0003-3939-3940)
- Vincent Yau (ORCID: https://orcid.org/0000-0001-5301-5300)
- Andy Surinach (ORCID: https://orcid.org/0000-0002-0743-7219)
- Jennie H. Best (ORCID: https://orcid.org/0000-0002-4616-5703)
- Marie-Hélène Blanchet Zumofen (ORCID: https://orcid.org/0000-0003-2760-2880)
- Hao Zhou (ORCID: https://orcid.org/0000-0002-1664-7111)
- Shih-Chen Chang
Institutions
- Roche (Switzerland) (CH)
- Roche (United Kingdom) (GB)
- Roche (Norway) (NO)
Publication Details
- Journal
- Infectious Diseases and Therapy
- Published
- 2024-08-16
- DOI
- https://doi.org/10.1007/s40121-024-01027-9
- Citations
- 6
- Primary Topic
- Influenza Virus Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.32
Funders
- F. Hoffmann-La Roche
- Genentech